Using email reminders to improve pneumococcal vaccine completion
Parents' Enhanced Reminder Intervention to Improve Children's Timely Completion of Immunization Series of Pneumococcal Vaccine at the 12-month's Visit
NA · Ottawa Hospital Research Institute · NCT06000397
This study is testing if sending better email reminders can help people using the CANImmunize app complete their pneumococcal vaccine series on time.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 700 (estimated) |
| Ages | 10 Months to 11 Months |
| Sex | All |
| Sponsor | Ottawa Hospital Research Institute (other) |
| Locations | 1 site (Ottawa) |
| Trial ID | NCT06000397 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate whether enhanced email reminders can increase the completion rates of the pneumococcal vaccine at the 12-month visit for users of the CANImmunize app. Participants will be randomly assigned to receive either enhanced reminder emails or standard notifications from the app. The study will compare the vaccine coverage rates between these two groups to determine the effectiveness of the enhanced reminders. Additionally, it will explore factors that predict timely completion of the vaccine series among participants.
Who should consider this trial
Good fit: Ideal candidates are parents or guardians of infants aged 10 to 11 months who have previously received the earlier doses of the pneumococcal vaccine.
Not a fit: Patients whose infants have not received prior doses of the pneumococcal vaccine or have inactive email addresses will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve immunization rates for pneumococcal vaccines in infants.
How similar studies have performed: Other studies have shown that reminder systems can effectively improve vaccination rates, suggesting this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria To be included in the study, CANImmunize account holders must have: * Enabled the reception to receive emails from CANImmunize, and * Record(s) for an infant aged between 10- and 11-months, who have already received the earlier doses of the pneumococcal vaccine in accordance with their provincial/territorial routine immunization schedule. Exclusion Criteria * The account holder (parent, or guardian of the child) has an inactive or undelivered email address, or * No record(s) for an infant aged 10- and 11-months, or * The record for the 10- or 11-month-old indicates that he/she has not received the prior pneumococcal vaccine doses.
Where this trial is running
Ottawa
- CANImmunize — Ottawa, Canada (RECRUITING)
Study contacts
- Study coordinator: Kathryn MacDonald
- Email: kathryn@canimmunize.ca
- Phone: 613-293-1193
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pneumococcal Vaccines, Immunization Coverage, Vaccine coverage, Vaccine uptake